

Matthias Preusser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8876202/publications.pdf>

Version: 2024-02-01

433
papers

25,544
citations

10986

71
h-index

9345

143
g-index

451
all docs

451
docs citations

451
times ranked

29395
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	27.6	826
3	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	10.7	816
4	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015, 528, 93-98.	27.8	787
5	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology</i> , The, 2016, 17, e383-e391.	10.7	627
6	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	10.7	586
7	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
8	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	4.3	530
9	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	1.2	485
10	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469
11	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
12	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. <i>Acta Neuropathologica</i> , 2011, 122, 11-19.	7.7	445
13	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	7.7	386
14	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017, 19, 162-174.	1.2	381
15	Current concepts and management of glioblastoma. <i>Annals of Neurology</i> , 2011, 70, 9-21.	5.3	380
16	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	30.7	359
17	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	10.7	340
18	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	21.4	315

#	ARTICLE	IF	CITATIONS
19	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	10.1	307
20	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	3.7	289
21	Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth <i>in vivo</i> . <i>Cancer Research</i> , 2007, 67, 11244-11253.	0.9	282
22	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmunology</i> , 2016, 5, e1057388.	4.6	239
23	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1821-1834.	1.2	230
24	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	30.7	229
25	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	1.2	213
26	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. <i>Acta Neuropathologica</i> , 2012, 123, 223-233.	7.7	204
27	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. <i>Blood</i> , 2012, 120, e28-e34.	1.4	199
28	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018, 4, 176-196.	7.4	194
29	Invasion patterns in brain metastases of solid cancers. <i>Neuro-Oncology</i> , 2013, 15, 1664-1672.	1.2	191
30	Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. <i>Brain Pathology</i> , 2008, 18, 520-532.	4.1	189
31	Initial efficacy of anti-lymphocyte activation gene-3 (anti-“LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-“PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9520-9520.	1.6	188
32	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
33	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 844-850.	3.7	177
34	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. <i>Acta Neuropathologica</i> , 2013, 125, 891-900.	7.7	177
35	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	21.4	177
36	The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 519.	1.6	165

#	ARTICLE	IF	CITATIONS
37	Visualization of Central European Tick-Borne Encephalitis Infection in Fatal Human Cases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 506-512.	1.7	164
38	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. <i>Blood</i> , 2017, 129, 1831-1839.	1.4	164
39	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	7.7	163
40	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. <i>Journal of Neuro-Oncology</i> , 2009, 95, 401-411.	2.9	157
41	PET imaging in patients with meningioma—report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017, 19, 1576-1587.	1.2	157
42	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
43	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. <i>ESMO Open</i> , 2016, 1, e000024.	4.5	152
44	Advances in meningioma genetics: novel therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2018, 14, 106-115.	10.1	148
45	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO—EONS—EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1306-1319.	1.2	146
46	PET imaging in patients with brain metastasis—report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	1.2	139
47	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. <i>PLoS ONE</i> , 2013, 8, e76988.	2.5	138
48	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	10.1	125
49	Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin. <i>Cancer Discovery</i> , 2018, 8, 1316-1331.	9.4	123
50	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. <i>Blood</i> , 2021, 137, 1669-1678.	1.4	123
51	Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. <i>Journal of NeuroVirology</i> , 2006, 12, 322-327.	2.1	121
52	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
53	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 13-22.	2.5	114
54	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	1.2	114

#	ARTICLE	IF	CITATIONS
55	Angiocentric Glioma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1709-1718.	3.7	110
56	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	2.9	107
57	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	3.3	103
58	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 702-710.	4.1	103
59	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)., 2014, 33, 42-49.		100
60	Tumourâ€infiltrating lymphocytes and expression of programmed death ligand 1 (PDâ€L1) in melanoma brain metastases. <i>Histopathology</i> , 2015, 66, 289-299.	2.9	99
61	Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the<i>IDH1-R132H</i> Mutation in Diffuse Glioma Biopsy Specimens. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 715-723.	1.7	98
62	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 51-60.	6.4	98
63	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 740-757.	1.7	95
64	High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, 532-541.	4.2	95
65	Glioma Survival Prediction with Combined Analysis of In Vivo ¹¹C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 892-899.	5.0	94
66	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
67	AKT1E17K mutations cluster with meningotheial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. <i>Acta Neuropathologica</i> , 2013, 126, 757-762.	7.7	88
68	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. <i>Neurosurgical Review</i> , 2012, 35, 381-391.	2.4	86
69	Dura mater is a potential source of AÎ² seeds. <i>Acta Neuropathologica</i> , 2016, 131, 911-923.	7.7	85
70	Imaging ex vivo healthy and pathological human brain tissue with ultra-high-resolution optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2005, 10, 011006.	2.6	82
71	Characterization of the inflammatory response to solid cancer metastases in the human brain. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 69-81.	3.3	81
72	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. <i>European Radiology</i> , 2017, 27, 3167-3173.	4.5	80

#	ARTICLE	IF	CITATIONS
73	Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. <i>Neuro-Oncology</i> , 2015, 17, 588-595.	1.2	79
74	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019, 4, e000507.	4.5	79
75	Neurocognitive training in patients with high-grade glioma: a pilot study. <i>Journal of Neuro-Oncology</i> , 2010, 97, 109-115.	2.9	78
76	The caregiversâ€™ perspective on the end-of-life phase of glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2013, 112, 403-411.	2.9	72
77	<i>BRAF</i> Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <i>CD</i> 34 Expression. <i>Brain Pathology</i> , 2014, 24, 221-229.	4.1	72
78	Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. <i>Translational Oncology</i> , 2012, 5, 56-64.	3.7	71
79	Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. <i>ESMO Open</i> , 2018, 3, e000262.	4.5	69
80	<i>PD</i> 1 and <i>PD</i> 1 expression in <i>HNSCC</i> primary cancer and related lymph node metastasis â€” impact on clinical outcome. <i>Histopathology</i> , 2018, 73, 573-584.	2.9	68
81	Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. <i>Cancer Biology and Therapy</i> , 2008, 7, 1377-1385.	3.4	67
82	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	3.7	67
83	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 357-368.	3.3	66
84	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	3.8	65
85	Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 727-739.	3.3	65
86	Rosette-forming glioneuronal tumor of the fourth ventricle. <i>Acta Neuropathologica</i> , 2003, 106, 506-508.	7.7	63
87	<i>NRAS</i> and <i>BRAF</i> Mutations in Melanoma-Associated Nevi and Uninvolved Nevi. <i>PLoS ONE</i> , 2013, 8, e69639.	2.5	63
88	High rate of <i>FGFR1</i> amplifications in brain metastases of squamous and non-squamous lung cancer. <i>Lung Cancer</i> , 2014, 83, 83-89.	2.0	63
89	High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. <i>PLoS ONE</i> , 2018, 13, e0207849.	2.5	63
90	Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. <i>Journal of Neuro-Oncology</i> , 2018, 140, 173-178.	2.9	62

#	ARTICLE	IF	CITATIONS
91	How we treat glioblastoma. <i>ESMO Open</i> , 2019, 4, e000520.	4.5	62
92	Breast cancer brain metastases responding to primary systemic therapy with T-DM1. <i>Journal of Neuro-Oncology</i> , 2014, 116, 205-206.	2.9	61
93	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. <i>Cancer Investigation</i> , 2012, 30, 615-621.	1.3	60
94	Interlaboratory comparison of IDH mutation detection. <i>Journal of Neuro-Oncology</i> , 2013, 112, 173-178.	2.9	59
95	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 278-283.	2.0	59
96	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	1.2	59
97	Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors. <i>Cancer</i> , 2006, 107, 162-170.	4.1	57
98	Trabectedin has promising antineoplastic activity in high-grade meningioma. <i>Cancer</i> , 2012, 118, 5038-5049.	4.1	57
99	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). <i>Neuro-Oncology</i> , 2014, 16, 92-102.	1.2	57
100	Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review. <i>Journal of Neuro-Oncology</i> , 2008, 90, 301-308.	2.9	56
101	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014, 23, 637-643.	2.2	56
102	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. <i>Neuro-Oncology</i> , 2019, 21, 1587-1594.	1.2	56
103	EANO's EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , 2019, 20, e715-e728.	10.7	56
104	Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1272.	2.4	56
105	IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. <i>Journal of Neuro-Oncology</i> , 2011, 30, 217-230.		55
106	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , 2014, 128, 879-891.	7.7	54
107	Nigral burden of α -synuclein correlates with striatal dopamine deficit. <i>Movement Disorders</i> , 2008, 23, 1608-1612.	3.9	53
108	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. <i>Thrombosis Research</i> , 2013, 131, 162-165.	1.7	53

#	ARTICLE	IF	CITATIONS
109	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	1.2	53
110	Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. <i>JAMA Oncology</i> , 2022, 8, 106.	7.1	53
111	α 3, α 5 and α 6 integrins in brain metastases of lung cancer. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 841-851.	3.3	51
112	Diffuse glioneuronal tumour with oligodendroglia-like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 422-430.	3.2	51
113	The inflammatory microenvironment in brain metastases: potential treatment target?. <i>Chinese Clinical Oncology</i> , 2015, 4, 21.	1.2	51
114	Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, e41-55.	3.2	49
115	Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. , 2012, 31, 352-360.		49
116	O ⁶ -methylguanine DNA methyltransferase immunorexpression in nonfunctioning pituitary adenomas. <i>Cancer</i> , 2009, 115, 1070-1080.	4.1	48
117	Exploratory investigation of eight circulating plasma markers in brain tumor patients. <i>Neurosurgical Review</i> , 2013, 36, 45-56.	2.4	48
118	Malignant glioma: <i>Neuropathology and Neurobiology</i> . <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 332-337.	1.1	46
119	5-ALA-induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients. <i>Neurosurgical Focus</i> , 2018, 44, E7.	2.3	46
120	Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. , 2014, 33, 6-14.		45
121	OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms. <i>Histopathology</i> , 2007, 50, 365-370.	2.9	44
122	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012, 60, 885-894.	2.9	44
123	Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. <i>Journal of Neuro-Oncology</i> , 2012, 109, 331-339.	2.9	43
124	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. <i>Pathology</i> , 2010, 42, 547-552.	0.6	42
125	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	1.2	42
126	Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. , 2015, 34, 250-257.		42

#	ARTICLE	IF	CITATIONS
127	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2079-TPS2079.	1.6	41
128	mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. <i>Cancer Letters</i> , 2010, 296, 249-256.	7.2	40
129	SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3554.	1.6	40
130	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. <i>Magnetic Resonance Imaging</i> , 2012, 30, 139-147.	1.8	39
131	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. <i>Tumor Biology</i> , 2016, 37, 1173-1182.	1.8	39
132	SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000889.	4.5	39
133	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A meta-analysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	7.7	39
134	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	4.5	38
135	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. <i>PLoS ONE</i> , 2013, 8, e55464.	2.5	38
136	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , 2012, 48, 3439-3447.	2.8	37
137	High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. <i>NeuroImage: Clinical</i> , 2020, 28, 102433.	2.7	37
138	MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. <i>Histology and Histopathology</i> , 2009, 24, 511-8.	0.7	37
139	microRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 679-692.	3.3	36
140	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1803-1811.	2.8	36
141	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. <i>Oncolmmunology</i> , 2018, 7, e1435226.	4.6	36
142	Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas. <i>Journal of Neurosurgery</i> , 2018, 129, 341-353.	1.6	35
143	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	4.5	35
144	Debatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.2	35

#	ARTICLE	IF	CITATIONS
145	Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. <i>Acta Neuropathologica</i> , 2005, 109, 211-216.	7.7	34
146	Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. <i>Journal of Neurosurgery</i> , 2009, 111, 563-571.	1.6	34
147	BRAF alterations in brain tumours. <i>Current Opinion in Neurology</i> , 2014, 27, 689-696.	3.6	34
148	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	2.8	34
149	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 2737-2744.	7.0	34
150	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	7.7	34
151	Papillary glioneuronal tumor. <i>Neuropathology</i> , 2007, 27, 468-473.	1.2	33
152	NephroCheck data compared to serum creatinine in various clinical settings. <i>BMC Nephrology</i> , 2015, 16, 206.	1.8	33
153	Prognostic role of tumour-infiltrating inflammatory cells in brain tumours. <i>Current Opinion in Neurology</i> , 2015, 28, 647-658.	3.6	33
154	High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T. <i>NeuroImage</i> , 2019, 191, 587-595.	4.2	33
155	Survivin Expression in Intracranial Ependymomas and Its Correlation With Tumor Cell Proliferation and Patient Outcome. <i>American Journal of Clinical Pathology</i> , 2005, 124, 543-549.	0.7	32
156	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). <i>Neuro-Oncology</i> , 2013, 15, 112-121.	1.2	31
157	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
158	The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. <i>Oncotarget</i> , 2018, 9, 6968-6976.	1.8	31
159	Non-invasive assessment of intratumoral vascularity using arterial spin labeling: A comparison to susceptibility-weighted imaging for the differentiation of primary cerebral lymphoma and glioblastoma. <i>European Journal of Radiology</i> , 2014, 83, 806-810.	2.6	30
160	Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study. <i>European Journal of Cancer</i> , 2022, 165, 184-194.	2.8	29
161	TPPP/p25 in brain tumours: expression in non-neoplastic oligodendrocytes but not in oligodendroglioma cells. <i>Acta Neuropathologica</i> , 2007, 113, 213-215.	7.7	28
162	Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1354-1360.	2.8	28

#	ARTICLE	IF	CITATIONS
163	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	1.8	28
164	Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension. <i>Basic Research in Cardiology</i> , 2020, 115, 58.	5.9	28
165	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e116-e122.	3.8	28
166	Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. <i>Cancer Cell</i> , 2022, 40, 444-446.	16.8	28
167	Optimal Management of Brain Metastases from Breast Cancer. <i>CNS Drugs</i> , 2013, 27, 121-134.	5.9	27
168	Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 159-164.	1.2	27
169	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. <i>Cancer</i> , 2020, 126, 4341-4352.	4.1	27
170	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	4.1	27
171	No prognostic impact of survivin expression in glioblastoma. <i>Acta Neuropathologica</i> , 2005, 109, 534-538.	7.7	26
172	Biology and Clinical Management Challenges in Meningioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e106-e115.	3.8	26
173	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. <i>European Radiology</i> , 2017, 27, 1556-1567.	4.5	26
174	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score. <i>Neuro-Oncology</i> , 2017, 19, now290.	1.2	26
175	Anti-angiogenic therapies in brain metastases. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 14-17.	0.5	26
176	Prevalence of pain and its association with symptoms of post-traumatic stress disorder, depression, anxiety and distress in 846 cancer patients: A cross sectional study. <i>Psycho-Oncology</i> , 2021, 30, 504-510.	2.3	26
177	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
178	Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism. <i>Neuropathology</i> , 2007, 27, 453-456.	1.2	25
179	Amplification and overexpression of <i>CMET</i> is a common event in brain metastases of non-small cell lung cancer. <i>Histopathology</i> , 2014, 65, 684-692.	2.9	25
180	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. <i>Breast Care</i> , 2014, 9, 134-134.	1.4	25

#	ARTICLE	IF	CITATIONS
181	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 370-377.	2.8	25
182	New developments in brain metastases. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878550.	3.5	25
183	Screening for post-traumatic stress disorders in 1017 cancer patients and correlation with anxiety, depression, and distress. <i>Psycho-Oncology</i> , 2019, 28, 2382-2388.	2.3	25
184	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198.	2.9	25
185	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25
186	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	7.0	25
187	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
188	Assessing MGMT methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	3.0	24
189	Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer. <i>European Journal of Radiology</i> , 2016, 85, 540-545.	2.6	24
190	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2698-2706.	1.5	24
191	Molecular biology of high-grade gliomas: what should the clinician know?. <i>Chinese Journal of Cancer</i> , 2014, 33, 4-7.	4.9	24
192	Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: Implications for differential diagnosis. <i>Neuropathology</i> , 2005, 25, 241-246.	1.2	23
193	ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM). <i>Neuro-Oncology</i> , 2019, 21, vi17-vi17.	1.2	23
194	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 46-55.	1.0	22
195	Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well-Preserved Histomorphology, Immunohistochemistry and Nucleic Acids. <i>Brain Pathology</i> , 2010, 20, 1010-1020.	4.1	22
196	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 771-778.	2.3	22
197	Role of the blood-brain barrier in metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 57-66.	1.8	22
198	Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas. <i>Neuro-Oncology</i> , 2018, 20, 411-419.	1.2	22

#	ARTICLE	IF	CITATIONS
199	Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. <i>Molecular Cancer Research</i> , 2021, 19, 688-701.	3.4	22
200	LAG-3 expression in the inflammatory microenvironment of glioma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 533-539.	2.9	22
201	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. <i>SpringerPlus</i> , 2014, 3, 111.	1.2	21
202	Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases. <i>British Journal of Cancer</i> , 2021, 124, 1294-1300.	6.4	21
203	Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. <i>Cancers</i> , 2021, 13, 566.	3.7	21
204	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	3.2	21
205	Brain metastasis. <i>Current Opinion in Neurology</i> , 2012, 25, 786-794.	3.6	20
206	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2012, 109, 323-330.	2.9	20
207	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. <i>Cancer Investigation</i> , 2012, 30, 625-629.	1.3	19
208	Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?. , 2012, 31, 405-408.		19
209	Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using ⁶⁸ Ga-Pentixafor PET/MRI. <i>Clinical Nuclear Medicine</i> , 2021, 46, 16-20.	1.3	19
210	Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. <i>Journal of Neurosurgery</i> , 2020, 133, 1032-1043.	1.6	19
211	Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma. , 2017, 36, 56-59.		19
212	Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. <i>Biomarkers in Medicine</i> , 2015, 9, 327-335.	1.4	18
213	In search of a target: PD-1 and PD-L1 profiling across glioma types. <i>Neuro-Oncology</i> , 2016, 18, 1331-1332.	1.2	18
214	A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 895.	4.8	18
215	Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. <i>European Journal of Cancer</i> , 2022, 162, 170-181.	2.8	18
216	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18

#	ARTICLE	IF	CITATIONS
217	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	4.5	17
218	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	2.8	17
219	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	4.5	17
220	Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?. <i>Cancers</i> , 2021, 13, 4632.	3.7	17
221	Elevated blood markers 1 year before manifestation of malignant glioma. <i>Neuro-Oncology</i> , 2010, 12, 1004-1008.	1.2	16
222	Circulating biomarkers of CNS tumors: an update. <i>Biomarkers in Medicine</i> , 2013, 7, 267-285.	1.4	16
223	BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 7-14.	4.1	16
224	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. <i>Neuro-Oncology</i> , 2019, 21, 234-241.	1.2	16
225	How we treat patients with brain tumour during the COVID-19 pandemic. <i>ESMO Open</i> , 2019, 4, e000789.	4.5	16
226	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021, 156, 93-108.	2.8	16
227	Frequent overexpression of ErbB " receptor family members in brain metastases of non-small cell lung cancer patients. <i>Apmis</i> , 2013, 121, 1144-1152.	2.0	15
228	ROS1 translocations and amplifications in lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 425-426.	2.9	15
229	Evaluation of Dose-Staged Gamma Knife Radiosurgical Treatment Method for High-Risk Brain Metastases. <i>World Neurosurgery</i> , 2016, 94, 352-359.	1.3	15
230	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. <i>Pathology and Oncology Research</i> , 2020, 26, 2225-2235.	1.9	15
231	Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. <i>Anticancer Research</i> , 2013, 33, 1065-71.	1.1	15
232	Positive troponin T without cardiac involvement in inclusion body myositis. <i>Human Pathology</i> , 2005, 36, 917-921.	2.0	14
233	Myxopapillary Ependymoma With Pleuropulmonary Metastases and High Plasma Glial Fibrillary Acidic Protein Levels. <i>Journal of Clinical Oncology</i> , 2011, 29, e756-e757.	1.6	14
234	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. <i>Journal of Neuro-Oncology</i> , 2013, 112, 347-354.	2.9	14

#	ARTICLE	IF	CITATIONS
235	High-grade meningiomas. <i>Current Opinion in Neurology</i> , 2013, 26, 708-715.	3.6	14
236	A step towards clinical blood biomarkers of glioblastoma. <i>Nature Reviews Neurology</i> , 2014, 10, 681-682.	10.1	14
237	Immunotherapy of Brain Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 326-334.	1.2	14
238	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 135-144.	4.4	14
239	Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis. <i>Cancer Biology and Therapy</i> , 2018, 19, 169-174.	3.4	14
240	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 996.	2.8	14
241	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. <i>Cancers</i> , 2020, 12, 2493.	3.7	14
242	Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. <i>BMC Cancer</i> , 2020, 20, 410.	2.6	14
243	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038.	0.7	14
244	A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR. , 2014, 33, 50-60.		14
245	Advances in brain tumour classification and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 71-72.	10.1	13
246	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. <i>Journal of Neuro-Oncology</i> , 2019, 145, 85-95.	2.9	13
247	Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?. <i>Nature Reviews Neurology</i> , 2019, 15, 314-315.	10.1	13
248	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. <i>Cancers</i> , 2019, 11, 2020.	3.7	13
249	Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases. <i>ESMO Open</i> , 2021, 6, 100057.	4.5	13
250	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2007-2007.	1.6	13
251	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	1.2	13
252	Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2004, 10, 6567-6571.	7.0	12

#	ARTICLE	IF	CITATIONS
253	No Evidence for BRAF-V600E Mutations in Gastroesophageal Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 426-430.	1.2	12
254	Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma. <i>Oncology</i> , 2015, 88, 173-179.	1.9	12
255	KINFix – A formalin-free non-commercial fixative optimized for histological, immunohistochemical and molecular analyses of neurosurgical tissue specimens. , 2016, 35, 3-12.		12
256	Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 965-975.	1.1	12
257	Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases. <i>Cancers</i> , 2021, 13, 603.	3.7	12
258	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
259	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 725903.	2.4	12
260	Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. <i>Radiology and Oncology</i> , 2010, 44, 113-20.	1.7	11
261	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. <i>Archives of Dermatological Research</i> , 2014, 306, 873-884.	1.9	11
262	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	4.5	11
263	Cancer immune cycle: a video introduction to the interaction between cancer and the immune system. <i>ESMO Open</i> , 2016, 1, e000056.	4.5	11
264	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	7.7	11
265	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. <i>Radiotherapy and Oncology</i> , 2019, 130, 139-148.	0.6	11
266	EORTC SPECTRA – A unique molecular profiling platform for adolescents and young adults with cancer in Europe. <i>International Journal of Cancer</i> , 2020, 147, 1180-1184.	5.1	11
267	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
268	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. <i>Journal of Personalized Medicine</i> , 2021, 11, 624.	2.5	11
269	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
270	Autopsy at 2 months after death: Brain is satisfactorily preserved for neuropathology. <i>Forensic Science International</i> , 2007, 168, 177-182.	2.2	10

#	ARTICLE	IF	CITATIONS
271	Pilot study on sex hormone levels and fertility in women with malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 387-394.	2.9	10
272	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. <i>Anti-Cancer Drugs</i> , 2014, 25, 723-728.	1.4	10
273	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <i>et</i> as a negative prognostic factor. <i>Histopathology</i> , 2015, 67, 799-805.	2.9	10
274	Haematopoietic stem cell transplantation for treatment of primary <i>CNS</i> lymphoma: single-centre experience and literature review. <i>European Journal of Haematology</i> , 2015, 95, 75-82.	2.2	10
275	Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis. <i>Hormones and Cancer</i> , 2020, 11, 42-51.	4.9	10
276	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	2.8	10
277	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	4.2	10
278	Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature. <i>Journal of Neurology</i> , 2022, 269, 1574-1590.	3.6	10
279	Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members. <i>Neuro-Oncology Practice</i> , 2022, 9, 105-113.	1.6	10
280	Biology in prevention and treatment of brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1339-1348.	2.4	9
281	microRNA-21 Expression is Elevated in Esophageal Adenocarcinoma After Neoadjuvant Chemotherapy. <i>Cancer Investigation</i> , 2015, 33, 246-250.	1.3	9
282	External validation of the NUn score for predicting anastomotic leakage after oesophageal resection. <i>Scientific Reports</i> , 2017, 7, 9725.	3.3	9
283	MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas. <i>Journal of Cancer</i> , 2018, 9, 460-468.	2.5	9
284	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. <i>Cancers</i> , 2020, 12, 3775.	3.7	9
285	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	3.2	9
286	MR Fingerprinting – A Radiogenomic Marker for Diffuse Gliomas. <i>Cancers</i> , 2022, 14, 723.	3.7	9
287	High plasma-GFAP levels in metastatic myxopapillary ependymoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 359-363.	2.9	8
288	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014, 9, 6-6.	1.4	8

#	ARTICLE	IF	CITATIONS
289	A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection. <i>Endoscopy International Open</i> , 2015, 03, E19-E28.	1.8	8
290	Milestones of the last 10 years. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.5	8
291	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. <i>Acta Oncologica</i> , 2019, 58, 967-976.	1.8	8
292	Applied Precision Cancer Medicine in Neuro-Oncology. <i>Scientific Reports</i> , 2019, 9, 20139.	3.3	8
293	p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction. <i>Cancers</i> , 2020, 12, 3205.	3.7	8
294	Does the application of diffusion weighted imaging improve the prediction of survival in patients with resected brain metastases? A retrospective multicenter study. <i>Cancer Imaging</i> , 2020, 20, 16.	2.8	8
295	Development of Randomized Trials in Adults with Medulloblastoma – The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	3.7	8
296	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open – Cancer Horizons pro and con discussion. <i>ESMO Open</i> , 2019, 4, e000565.	4.5	8
297	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. , 2012, 31, 206-209.		8
298	Analysis of the inflammatory tumor microenvironment in meningeal neoplasms. , 2020, 39, 256-262.		8
299	Secretagogin expression in tumours of the human brain and its coverings. <i>Apmis</i> , 2007, 115, 319-326.	2.0	7
300	Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. <i>Cancer Biology and Therapy</i> , 2010, 9, 919-927.	3.4	7
301	Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, e13-e17.	3.7	7
302	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 351-353.	1.2	7
303	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
304	Postoperative Magnetic Resonance Imaging After Surgery of Brain Metastases: Analysis of Extent of Resection and Potential Risk Factors for Incomplete Resection. <i>World Neurosurgery</i> , 2020, 143, e365-e373.	1.3	7
305	Targeted Therapy Recommendations for Therapy Refractory Solid Tumors – Data from the Real-World Precision Medicine Platform MONDTI. <i>Journal of Personalized Medicine</i> , 2020, 10, 188.	2.5	7
306	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. <i>Cancers</i> , 2020, 12, 301.	3.7	7

#	ARTICLE	IF	CITATIONS
307	Impact of COVID-19 lockdown on routine oncology versus emergency care at a high volume cancer centre. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13623.	3.4	7
308	Outcome evaluation in glioblastoma patients older than 65 years: Importance of individual assessment of treatment tolerance. , 2014, 33, 399-406.		7
309	The cancer survival index™ A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
310	Development of “Core Outcome Sets”™ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings. <i>BMJ Open</i> , 2022, 12, e057384.	1.9	7
311	CSF and laboratory analysis (tumor markers). <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 104, 143-148.	1.8	6
312	ALKgene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. <i>Apmis</i> , 2014, 122, 867-872.	2.0	6
313	Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. <i>Anti-Cancer Drugs</i> , 2015, 26, 579-581.	1.4	6
314	The future of targeted therapies for brain metastases. <i>Future Oncology</i> , 2015, 11, 2315-2327.	2.4	6
315	Case-Based Review: meningioma. <i>Neuro-Oncology Practice</i> , 2016, 3, 120-134.	1.6	6
316	New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open “ Cancer Horizons” Series. <i>ESMO Open</i> , 2019, 4, e000501.	4.5	6
317	Antiangiogenic Treatment of Meningiomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 359.	1.8	5
318	Evidence-based management of adult patients with diffuse glioma “ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431.	10.7	5
319	Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling. <i>Clinical Neuroradiology</i> , 2020, 30, 599-605.	1.9	5
320	3630 Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020. <i>Annals of Oncology</i> , 2020, 31, S397.	1.2	5
321	Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 779-786.	2.0	5
322	Brain metastasis research: a late awakening. <i>Chinese Clinical Oncology</i> , 2015, 4, 17.	1.2	5
323	Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types. , 2016, 35, 89-92.		5
324	Opportunities and challenges for the development of “core outcome sets” in neuro-oncology. <i>Neuro-Oncology</i> , 2022, 24, 1048-1055.	1.2	5

#	ARTICLE	IF	CITATIONS
325	Enhanced expression of autophagy-related p62 without increased deposits of neurodegeneration-associated proteins in glioblastoma and surrounding tissue – An autopsy-based study. <i>Brain Pathology</i> , 2022, 32, e13058.	4.1	5
326	Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma – molecular testing procedures under scrutiny. , 2013, 32, 82-83.		4
327	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	4.5	4
328	Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3313-3322.	2.5	4
329	Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome. <i>ESMO Open</i> , 2020, 5, e000623.	4.5	4
330	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647.	4.5	4
331	PD1 and PD-L1 expression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2011-2011.	1.6	4
332	Lymphocyte-activation gene 3 (LAG-3) expression in the inflammatory microenvironment of glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2553-2553.	1.6	4
333	External granular cell layer bobbling: a distinct histomorphological feature of the developing human cerebellum. , 2013, 32, 42-50.		4
334	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.	4.5	4
335	Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non-small cell lung cancer. <i>Journal of Neurosurgery</i> , 2022, 137, 999-1005.	1.6	4
336	A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?. <i>Annals of Hematology</i> , 2015, 94, 345-346.	1.8	3
337	CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology. <i>ESMO Open</i> , 2017, 2, e000194.	4.5	3
338	Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment. <i>Neuro-Oncology</i> , 2017, 19, 1280-1282.	1.2	3
339	Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2021, 53, 287-293.	0.7	3
340	Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. <i>European Journal of Surgical Oncology</i> , 2022, 48, 383-390.	1.0	3
341	Plasma PD-L1 concentration in patients with brain metastases from solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13026-e13026.	1.6	3
342	Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy. <i>Pharmaceutics</i> , 2022, 14, 662.	4.5	3

#	ARTICLE	IF	CITATIONS
343	7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors. <i>Cancers</i> , 2022, 14, 2163.	3.7	3
344	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. <i>European Journal of Clinical Investigation</i> , 2011, 41, 539-545.	3.4	2
345	Bilateral retinal detachment in reactive arthritis: coincidence or association?. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 202-203.	1.9	2
346	Downregulation of CIC Does Not Associate with Overexpression of ETV1 or MAP Kinase Pathway Activation in Gastrointestinal Stromal Tumors. <i>Cancer Investigation</i> , 2014, 32, 363-367.	1.3	2
347	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and C W Bruyn, 2018, 145, 547-560.	1.8	2
348	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. <i>Journal of Neurosurgery</i> , 2018, 129, 1104-1105.	1.6	2
349	Introducing a new ESMO Open article series: how I treat side effects of immunotherapy. <i>ESMO Open</i> , 2020, 4, e000552.	4.5	2
350	SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 909-914.	1.9	2
351	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. <i>EJNMMI Research</i> , 2019, 9, 110.	2.5	2
352	Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 530-545.	1.4	2
353	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. <i>Neuro-Oncology Advances</i> , 2021, 3, v35-v42.	0.7	2
354	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	3.7	2
355	SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.9	2
356	DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case–Control Study. <i>Frontiers in Oncology</i> , 2022, 12, 811729.	2.8	2
357	Clinically useful biomarkers in neurooncology. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 201-204.	0.5	1
358	Primary systemic treatment of breast-cancer brain metastases. <i>Lancet Oncology</i> , The, 2013, 14, 8-9.	10.7	1
359	Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1079-1083.	1.0	1
360	OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients. <i>Neuro-Oncology</i> , 2019, 21, iii5-iii5.	1.2	1

#	ARTICLE	IF	CITATIONS
361	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	1.2	1
362	53. Genomic characterization of brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Cancer Genetics</i> , 2020, 244, 20-21.	0.4	1
363	Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 450-452.	0.5	1
364	Androgen Receptor is Expressed in Breast Cancer Brain Metastases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 728-733.	1.2	1
365	Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2059-2059.	1.6	1
366	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1130-1130.	1.6	1
367	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2012-2012.	1.6	1
368	T-DM1 in HER2-positive breast cancer brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 650-650.	1.6	1
369	Correlation of plasma PD-L1 detectability with age in glioma patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13039-e13039.	1.6	1
370	Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2072-2072.	1.6	1
371	PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8563-8563.	1.6	1
372	Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3562-3562.	1.6	1
373	Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9055-9055.	1.6	1
374	DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18527-e18527.	1.6	1
375	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , 2021, 23, vi126-vi127.	1.2	1
376	Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. <i>Anticancer Research</i> , 2020, 40, 6229-6236.	1.1	1
377	NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. <i>Neuro-Oncology</i> , 2020, 22, ii129-ii129.	1.2	1
378	Dermatitis linearis outbreak associated with <i>Paederus balcanicus</i> in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 511-515.	1.9	1

#	ARTICLE	IF	CITATIONS
379	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
380	Antiangiogenic treatment approaches in breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 397-406.	0.2	0
381	New frontiers in neurooncology. <i>Current Opinion in Neurology</i> , 2015, 28, 626-627.	3.6	0
382	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 70-75.	0.5	0
383	CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. <i>Neuro-Oncology</i> , 2018, 20, vi59-vi59.	1.2	0
384	MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE. <i>Neuro-Oncology</i> , 2018, 20, vi148-vi149.	1.2	0
385	MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi155-vi155.	1.2	0
386	Âcase report of pseudo-progression after pembrolizumab in metastatic gastric cancer and aÂreview of immunotherapy in gastroesophageal tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 51-59.	0.5	0
387	Tumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases. <i>Annals of Oncology</i> , 2019, 30, v148.	1.2	0
388	Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases. <i>Annals of Oncology</i> , 2019, 30, v152.	1.2	0
389	SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i33-i33.	0.7	0
390	A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis. <i>Annals of Oncology</i> , 2019, 30, iv67.	1.2	0
391	ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?. <i>Neuro-Oncology Advances</i> , 2019, 1, ii16-ii16.	0.7	0
392	LS2 METASTATIC BRAIN TUMORS / MENINGIOMAS: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES. <i>Neuro-Oncology Advances</i> , 2019, 1, ii2-ii3.	0.7	0
393	P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer. <i>Neuro-Oncology</i> , 2019, 21, iii91-iii91.	1.2	0
394	EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe. <i>Annals of Oncology</i> , 2019, 30, vii34-vii35.	1.2	0
395	Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment. <i>ESMO Open</i> , 2020, 5, e000734.	4.5	0
396	362O Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma. <i>Annals of Oncology</i> , 2020, 31, S397.	1.2	0

#	ARTICLE	IF	CITATIONS
397	372MO Melanoma leptomeningeal metastases: A European multicenter cohort. <i>Annals of Oncology</i> , 2020, 31, S400-S401.	1.2	0
398	1953P Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumours: Data from the real-world precision medicine platform MONDTI. <i>Annals of Oncology</i> , 2020, 31, S1100.	1.2	0
399	1824P Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors. <i>Annals of Oncology</i> , 2020, 31, S1051-S1052.	1.2	0
400	1877P Fatigue changes according to systemic therapy type in patients with advanced solid cancer. <i>Annals of Oncology</i> , 2020, 31, S1069.	1.2	0
401	1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria. <i>Annals of Oncology</i> , 2020, 31, S1000.	1.2	0
402	1462P Prognostic impact of clinical and laboratory nutritional markers in resectable gastroesophageal cancer. <i>Annals of Oncology</i> , 2020, 31, S916.	1.2	0
403	1487P Prognostic impact of thyroid hormone status in resectable gastroesophageal cancer. <i>Annals of Oncology</i> , 2020, 31, S924.	1.2	0
404	Best of ASCO 2020. Memo - Magazine of European Medical Oncology, 2021, 14, 7-8.	0.5	0
405	BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI. <i>Neuro-Oncology Advances</i> , 2021, 3, i1-i1.	0.7	0
406	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 1208-1209.	1.2	0
407	Reply to comment on "Analysis of the inflammatory tumor microenvironment in meningeal neoplasms", 2021, 40, 170.		0
408	Systemic and local inflammation characteristics in patients with cancer after lung transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, e14527-e14527.	1.6	0
409	SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. <i>Neuro-Oncology Advances</i> , 2021, 3, iii25-iii25.	0.7	0
410	Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106841.	1.4	0
411	Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. <i>Cancers</i> , 2021, 13, 5050.	3.7	0
412	Correlation of large brain edema with favorable prognosis in patients with single brain metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 2053-2053.	1.6	0
413	Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2071-2071.	1.6	0
414	Blood alterations preceding clinical manifestation of glioblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2024-2024.	1.6	0

#	ARTICLE	IF	CITATIONS
415	QOL and neurocognitive functions in patients with GBM.. Journal of Clinical Oncology, 2014, 32, 2062-2062.	1.6	0
416	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases.. Journal of Clinical Oncology, 2015, 33, e13034-e13034.	1.6	0
417	Prognostic impact of breast cancer (BC) subtype in elderly patients.. Journal of Clinical Oncology, 2015, 33, e20536-e20536.	1.6	0
418	Trabectedin for Recurrent Grade II or III Meningioma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group. Neuro-Oncology Practice, 2015, 5, 44-44.	1.6	0
419	Identification of single nucleotide polymorphism of PI3k-AKT-TOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.. Journal of Clinical Oncology, 2017, 35, 2007-2007.	1.6	0
420	The value of ¹⁸ F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. Journal of Clinical Oncology, 2017, 35, 2076-2076.	1.6	0
421	Meningioma research – status quo and quo vadis. Chinese Clinical Oncology, 2017, 6, S1-S1.	1.2	0
422	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
423	Correlation of systemic and local inflammation with survival prognosis in glioma patients.. Journal of Clinical Oncology, 2019, 37, 2052-2052.	1.6	0
424	Current Treatment Strategies in Breast Cancer Brain Metastases. , 2020, , 267-279.		0
425	Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases.. Journal of Clinical Oncology, 2020, 38, 2528-2528.	1.6	0
426	Abstract 4729: Identifying genomic drivers of lung adenocarcinoma brain metastases. , 2020, , .		0
427	Abstract 3151: Active immunization with PD1-derived mimotope-Combination immunotherapy against Her-2/neu-expressing tumors. , 2020, , .		0
428	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. Neuro-Oncology, 2021, 23, vi130-vi130.	1.2	0
429	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. Neuro-Oncology, 2021, 23, vi123-vi124.	1.2	0
430	CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM. Neuro-Oncology, 2020, 22, ii54-ii54.	1.2	0
431	Toxicity management in severe and refractory cases – what we have learned. Memo - Magazine of European Medical Oncology, 2022, 15, 4-4.	0.5	0
432	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2055-2055.	1.6	0

#	ARTICLE	IF	CITATIONS
433	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. Journal of Clinical Oncology, 2022, 40, 2026-2026.	1.6	0